Major Adverse Cardiovascular Events: Risk Factors in Patients with RA Treated with Tofacitinib

被引：0
|
作者：
Charles-Schoeman, Christina [1 ]
Valdez, Hernan [2 ]
Soma, Koshika [2 ]
Hwang, Lie-Ju [2 ]
DeMasi, Ryan [2 ]
Boy, Mary [3 ]
McInnes, Iain B. [4 ]
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Pfizer Inc, New York, NY USA
[3] Pfizer Inc, Groton, CT 06340 USA
[4] Univ Glasgow, Glasgow Biomed Res Ctr, Glasgow, Lanark, Scotland
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3024
引用
收藏
页数：5
相关论文
共 50 条
  • [1] MAJOR ADVERSE CARDIOVASCULAR EVENTS: RISK FACTORS IN PATIENTS WITH RA TREATED WITH TOFACITINIB
    Charles-Schoeman, C.
    Valdez, H.
    Soma, K.
    Hwang, L.
    DeMasi, R.
    Boy, M.
    McInnes, I. B.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1034 - 1035
  • [2] RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR (CV) EVENTS (MACE) IN RHEUMATOID ARTHRITIS (RA) PATIENTS TREATED WITH TOCILIZUMAB (TCZ)
    Rao, V. U.
    Pavlov, A.
    Klearman, M.
    Musselman, D.
    Giles, J. T.
    Bathon, J. M.
    Sattar, N.
    Lee, J. S.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 356 - 357
  • [3] RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOCILIZUMAB
    Rao, Vijay
    Pavlov, Andrey
    Klearman, Micki
    Musselman, Dave
    Giles, Jon
    Bathon, Joan
    Sattar, Naveed
    Lee, Janet
    RHEUMATOLOGY, 2012, 51 : 138 - 138
  • [4] Risk Factors for Major Adverse Cardiovascular Events in Rheumatoid Arthritis Patients Treated with Tocilizumab
    Rao, Vijay
    Pavlov, Andrey
    Klearman, Micki
    Musselman, David
    Giles, Jon T.
    Bathon, Joan M.
    Sattar, Naveed
    Lee, Janet S.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S642 - S642
  • [5] Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme
    Schreiber, Stefan
    Rubin, David T.
    Ng, Siew C.
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    Modesto, Irene
    Guo, Xiang
    Su, Chinyu
    Kwok, Kenneth K.
    Jo, Hyejin
    Chen, Yan
    Yndestad, Arne
    Reinisch, Walter
    Dubinsky, Marla C.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 (11): : 1761 - 1770
  • [6] Major Cardiovascular Adverse Events by Baseline Cardiovascular Risk Stratification in Patients With Ulcerative Colitis Treated With Tofacitinib: Data From the OCTAVE Clinical Program
    Schreiber, Stefan
    Rubin, David T.
    Ng, Siew C.
    Modesto, Irene
    Guo, Xiang
    Su, Chinyu
    Kwok, Kenneth K.
    Jo, Hyejin
    Chen, Yan
    Yndestad, Arne
    Reinisch, Walter
    Dubinsky, Marla C.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S551 - S552
  • [7] Cardiovascular risk factors and the risk of major adverse limb events in patients with symptomatic cardiovascular disease
    Hageman, Steven H. J.
    de Borst, Gert Jan
    Dorresteijn, Johannes A. N.
    Bots, Michiel L.
    Westerink, Jan
    Asselbergs, Folkert W.
    Visseren, Frank L. J.
    HEART, 2020, 106 (21) : 1686 - 1692
  • [8] Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
    Charles-Schoeman, Christina
    DeMasi, Ryan
    Valdez, Hernan
    Soma, Koshika
    Hwang, Lie-Ju
    Boy, Mary G.
    Biswas, Pinaki
    McInnes, Iain B.
    ARTHRITIS & RHEUMATOLOGY, 2019, 71 (09) : 1450 - 1459
  • [9] Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
    Dougados, Maxime
    Charles-Schoeman, Christina
    Szekanecz, Zoltan
    Giles, Jon T.
    Ytterberg, Steven R.
    Bhatt, Deepak L.
    Koch, Gary G.
    Vranic, Ivana
    Wu, Joseph
    Wang, Cunshan
    Kwok, Kenneth
    Menon, Sujatha
    Connell, Carol A.
    Yndestad, Arne
    Rivas, Jose L.
    Buch, Maya H.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (04) : 575 - 577
  • [10] IMPACT OF BASELINE CARDIOVASCULAR RISK ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TOFACITINIB RHEUMATOID ARTHRITIS CLINICAL PROGRAMME
    Dougados, M.
    Charles-Schoeman, C.
    Szekanecz, Z.
    Giles, J. T.
    Ytterberg, S. R.
    Bhatt, D. L.
    Koch, G. G.
    Vranic, I.
    Wu, J.
    Wang, C.
    Kwok, K.
    Menon, S.
    Connell, C. A.
    Yndestad, A.
    Rivas, J. L.
    Buch, M. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 175 - 176
12345